ALPHAMAB-B(09966) signed a technology development contract with Suzhou Fortune Jerry.

ALPHAMAB-B(09966) announced that its wholly-owned subsidiary Jiangsu Kangning Jerui Biopharmaceutical Co., Ltd. has entered into a technology development contract with Suzhou Kangning Jerui Biotechnology Co., Ltd. on August 8, 2025. According to this agreement, Jiangsu Kangning Jerui has agreed to commission Suzhou Kangning Jerui to provide technical development services, including developing production processes and analytical methods for double-specific antibody-drug conjugate (ADC) candidate drugs, preparing samples for toxicology studies and new drug clinical trial (IND) application, conducting quality and stability studies on relevant samples, and assisting with IND registration. Suzhou Kangning Jerui has significant experience and competitiveness in process optimization services related to the technology development contract and has been a reliable service provider for the company since 2018. Therefore, they are very familiar with the company's needs and requirements. Considering the quality of the technical development services provided by Suzhou Kangning Jerui, the convenience and confidentiality of future technology transfer, and the competitiveness of the offer compared to other independent third-party suppliers, the company believes that the technology development contract will help optimize existing production and R&D processes, reduce related costs, and have a positive impact on the company's research, manufacturing, and IND applications for future products.